Mary‐Beth Joshi

High Gene Expression of <i>TS1</i>, <i>GSTP1</i>, and <i>ERCC1</i> Are Risk Factors for Survival in Patients Treated with Trimodality Therapy for Esophageal Cancer

Mary‐Beth Joshi, Yoshinori Shirota, Kathleen D. Danenberg et al. · Clinical Cancer Research · 2005 · 138 citations · Full text

Neighborhood‐level socioeconomic determinants impact outcomes in nonsmall cell lung cancer patients in the Southeastern United States

Loretta Erhunmwunsee, Mary‐Beth Joshi, Debbi H. Conlon et al. · Cancer · 2012 · 70 citations · Full text

Measurement of chemoresistance markers in patients with stage iii non–small cell lung cancer: a novel approach for patient selection

Kelli Brooks, Kathleen To, Mary‐Beth Joshi et al. · The Annals of Thoracic Surgery · 2003 · 51 citations

Prognostic Biomarkers, Chemoresistance Markers, Cancer Detection +9

Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial

Samuel M. Brown, Christina E. Barkauskas, Birgit Grund et al. · The Lancet Respiratory Medicine · 2023 · 19 citations · Full text

Covid-19 Pandemic, Antiviral Therapy, Respiratory Infection +6

Consensus-Driven Development of a Terminology for Biobanking, the Duke Experience

Helena Ellis, Mary‐Beth Joshi, Aenoch J. Lynn et al. · Biopreservation and Biobanking · 2017 · 13 citations · Full text

Terminology Management, Duke University, Engineering +19